The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

A survey of adults living with obesity and their physicians across seven countries reveals a high disconnect between their ...

Deaths attributed to both acute heart attack and obesity rose between 2007 and 2019, according to findings from the CDC ...

Queen Latifah opens up about obesity and heart health risks for public awareness campaign, Truth About Weight.

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

I worry about how these changes, which are occurring at the age of 13 or 14, might affect them later in life,” the study’s ...

A first-in-human study of an investigational once-daily oral treatment for obesity (SYNT-101) demonstrates positive ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...